



Media Release 30 March 2023

Melbourne, Australia

COVIRIX Medical Pty Ltd, based in Melbourne, an Australian pharmaceutical company dedicated to repurpose and develop antiviral and anti-inflammatory drugs for treatment of pulmonary diseases, is delighted to advise that IP Australia has granted a 20 years patent for the company's repurposed antiviral treatment and prevention of pulmonary infections. The antiviral treatment of COVIRIX Medical is designed to be administered by oral inhalation which COVIRIX Medical believes will provide a targeted treatment solution for COVID-19, which offers the prospect of faster onset of action and reduced side effects compared to systemic (oral) drugs.

In granting the Australian patent, The Australian Patent Office (IP Australia) has accepted that the company's invention is novel, inventive, and patentable.

COVIRIX Medical has proceeded to file further patent applications based on its international (Patent Cooperation Treaty) patent application in a number of significant offshore jurisdictions namely the US, EU, China, and Japan to seek patent protection for the company's invention.

COVIRIX Medical plans to partner with major pharmaceutical companies including those with proprietary inhalational drug delivery devices to support the introduction of its inhaled antiviral drug to the world. COVIRIX Medical was founded by a number of renowned professionals with long experience in pulmonary and cardiac healthcare, drug development and synthesis, inhalational drug delivery technology, and investment banking.

The World Health Organisation has declared since the beginning of 2023 that the Covid pandemic is continuing. The WHO Emergency Committee issued a report on 30 January 2023 which while elaborating on a number of issues, says this:

“The WHO Secretariat specifically highlighted its support to States Parties to: maintain multiple component surveillance systems; implement sentinel surveillance using a coordinated global approach to characterize known and emerging variants; strengthen COVID-19 clinical care pathways; provide regular updates to the COVID-19 guidelines; **increase access to therapeutics**, vaccines and diagnostics; and continue to conduct Unity studies which provide valuable information about seroprevalence globally.”

COVIRIX is pleased to be able to contribute to the arsenal of therapeutics to be used by the global healthcare system to help in the treatment of COVID-19. Since our drug candidates are broad spectrum in nature, they will possibly also be applicable to a range of other respiratory diseases.

For further reference on COVIRIX Medical please visit [Home \(covirix.com\)](https://www.covirix.com).

For discussion on this media release, please email COVIRIX Medical at contact@covirix.com.